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Teratoma formation by human embryonic stem cells:
Evaluation of essential parameters for future
safety studies
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b Department of Pathology, National University Health System, 5 Lower Kent Ridge Road, 119074 SingaporeReceived 5 December 2008; received in revised form 23 January 2009; accepted 4 February 2009Abstract Transplantation of human embryonic stem cells (hESC) into immune-deficient mice leads to the formation of
differentiated tumors comprising all three germ layers, resembling spontaneous human teratomas. Teratoma assays are
considered the gold standard for demonstrating differentiation potential of pluripotent hESC and hold promise as a standard
for assessing safety among hESC-derived cell populations intended for therapeutic applications. We tested the potency of
teratoma formation in seven anatomical transplantation locations (kidney capsule, muscle, subcutaneous space, peritoneal
cavity, testis, liver, epididymal fat pad) in SCID mice with and without addition of Matrigel, and found that intramuscular
teratoma formation was the most experimentally convenient, reproducible, and quantifiable. In the same experimental
setting, we compared undifferentiated hESC and differentiated populations enriched for either beating cardiomyocytes or
definitive endoderm derivatives (insulin-secreting beta cells), and showed that all cell preparations rapidly formed teratomas
with varying percentages of mesoderm, ectoderm, and endoderm. In limiting dilution experiments, we found that as little as
two hESC colonies spiked into feeder fibroblasts produced a teratoma, while a more rigorous single-cell titration achieved a
detection limit of 1/4000. In summary, we established core parameters essential for facilitating safety profiling of hESC-
derived products for future therapeutic applications.
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Human embryonic stem cells (hESC) are derived from the
inner cell mass of blastocyst-stage preimplantation embryos.
hESC are characterized by their cardinal properties of self-
renewal and pluripotency, i.e., the ability to differentiate
into derivatives of the three embryonic germ layers. Since
hESC were first isolated in 1994 (Bongso et al., 1994) and
later shown to propagate as individual lines in vitro
(Thomson et al., 1998), they have attracted enormous
attention due to their potential use as raw material for the
production of therapeutically useful cell types such as.
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(Hentze et al., 2007; Keller, 2005; Vogel, 2005). This
prospect has led to the development of numerous in vitro
directed differentiation protocols. To date, however, most
preparations of differentiated hESC are merely enriched for
the cell type of interest, and the presence of unknown,
confounding, and possible tumor-promoting cell types raises
broad alarm about not only the future clinical efficacy of this
material but also its safety.
hESC like their mouse counterpart cells form benign
tumors in immunodeficient mice (Damjanov and Andrews,
2007; Solter, 2006). These tumors are reminiscent of
spontaneous human teratomas that arise most commonly
in the gonads and comprise to varying degrees endoder-
mal, mesodermal, and ectodermal derivatives (Gertow et
al., 2007). Thus, this in vivo assay serves as a robust and
relatively simple way to demonstrate pluripotency.
Furthermore, given the obvious ethical challenges con-
cerning the generation of chimeric embryos by injecting
hESC into supernumerary human blastocysts (Leist et al.,
2008) and the poor contribution of hESC when trans-
planted into mouse host blastocysts, teratoma formation
essentially serves as the only available measure for
confirming pluripotency in vivo (Adewumi et al., 2007;
Brivanlou et al., 2003; Gertow et al., 2007). For example,
amniotic stem cell lines were recently shown to exhibit
incomplete pluripotency, while human-induced pluripotent
stem (iPS) cells readily formed bona fide teratomas in SCID
mice (De Coppi et al., 2007; Takahashi et al., 2007; Yu et
al., 2007).
A series of recent studies shows that teratoma formation
is strongly dependent on the site of engraftment. Teratomas
have been produced by hESC transplantation into the testis
(Gertow et al., 2004; Przyborski, 2005; Stojkovic et al.,
2005), kidney capsule (Blum and Benvenisty, 2007), liver
(Cooke et al., 2006), hind leg muscle (Amit et al., 2003; Choo
et al., 2004; Plaia et al., 2006; Tzukerman et al., 2006) and
and into the subcutaneous space (Cooke et al., 2006;
Prokhorova et al., 2008). Two recent studies systematically
compared teratoma formation in diverse locations (Cooke et
al., 2006; Prokhorova et al., 2008); they both concluded that
subcutaneous implantation is most permissive. However,
neither of these studies comprehensively examined tera-
toma growth over time or attempted to define a minimum
number of cells required to seed a teratoma. In contrast,
Lawrenz et al. (2004) performed rigorous titration studies
with an emphasis on teratoma growth kinetics and detection
limits using mouse embryonic stem cells (mESC). Defined
numbers of single-cell mESC (the J1 line) were mixed with a
population of non-neoplastic MRC-5 fibroblasts before
injection into immunocompromised mice (Lawrenz et al.,
2004). The detection limit of this assay was determined to
be 20 individual mESC spiked into a 2×106 cell inoculum in
100% of attempts, i.e., 1×10- 5 or 0.001%. Similarly,
establishing the sensitivity of the teratoma assay on a per
cell basis and standardizing how teratoma formation is
measured across laboratories will allow the tumor-forming
potential of cell populations intended for transplantation to
be carefully quantified and to address systematically the
mounting regulatory requirements promulgated by the US
Food and Drug Administration, FDA (Halme and Kessler,
2006).In our previous studies, we found that hESC differentiated
for extended periods of time were still able to form
teratomas (Phillips et al., 2007; Xu et al., 2008). In contrast,
several other reports characterizing differentiated hESC
(Kroon et al., 2008; Laflamme et al., 2005; Reubinoff et
al., 2001; Tomescot et al., 2007; Zhang et al., 2001) or mESC
(Guo et al., 2006; Kumashiro et al., 2005) populations
observed infrequent to no teratoma formation in various
animal models. Several of these prior studies suffer from the
entire absence of positive controls, insufficient in vivo time
scales, or lack of histological and immunocytochemical
characterization of the recovered hESC-derived material.
Having future hESC safety studies in mind, we initiated a
series of experiments guided by the mESC study of Lawrenz
et al. (2004). We used a number of hESC lines in SCID mice
and found that intramuscular injection is the most robust
location for teratoma formation and also easiest to grade.
We were further able to correlate hESC numbers and
teratoma growth kinetics when using defined numbers of
hESC colonies or trypsin-adapted hESC spiked into supportive
feeder cells.
Results
Site-dependent formation and grading of hESC
teratomas in SCID mice
In a limited series of initial experiments, we explored a
variety of transplantation sites for their susceptibility to
form hESC-derived teratomas with the aim of identifying
one that is easy to inject and readily allows teratoma
formation. Additionally, the requirement of Matrigel for
teratoma formation was assessed (Fig. 1A). We were
interested in evaluating whether teratomas occur in all
locations, and whether each site promotes excessive
formation of cysts. We found that all teratomas that grew
within 8 weeks after hESC injection in the kidney capsule,
body cavity (intraperitoneal/ip), testis, epididymal fat pad,
and liver parenchyma contained pronounced liquid-filled
cysts, which hampered histological analysis. Notably, injec-
tion of hESC subcutaneously gave rise to palpable teratomas
when Matrigel was coinjected (3/3 animals) but not in the
absence of Matrigel (3/3 animals). These tumors grew
slowly, were cyst free, dense, and hard to process for
histology. In our hands, hESC teratomas formed well without
Matrigel and in the absence of any cyst formation when
injected intramuscularly (im, 3/3 animals). Although the
animal numbers of this study were low, we confirmed this
positive result using numerous hESC lines in subsequent
experiments. Intramuscular teratomas were robustly gener-
ated with hES2 and hES4 (not shown), and with the cGMP
(current good manufacturing practice)-compliant lines ESI-
014, ESI-017, ESI-035, ESI-049, ESI-051, and ESI-053 (Crook
et al., 2007). Fig. 1B illustrates the typical histology of a
mature well-differentiated teratoma with all three germ
layers (endoderm, mesoderm, and ectoderm).
We next characterized the intramuscular teratomas
further by immunhistochemistry with typical differentiation
markers: anti-desmin staining (Fig. 2A) revealed smooth
muscle layers (mesoderm); anti-GFAP staining (Fig. 2B)
detected the dispersed presence of glia-like structures
200 H. Hentze et al.
Figure 2 Presence of all threeprimary germ-layer derivatives in a prototypical intramuscular teratoma. Sections froma single 12-week
intramuscular teratoma were stained with assorted antibodies: (A) anti-desmin (mesoderm/muscle); (B) anti-GFAP (ectoderm/neural
epithelium); (C) anti-endoA (keratinized endodermal epithelium); and (D) anti-Ki67 (proliferating cells). Magnifications as indicated.
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glandular endodermal structures (Fig. 2C). We also per-
formed anti-Ki67 staining which identifies proliferating cells.Figure 1 Teratoma formation after injection of hESC in different a
injected in seven different engraftment locations into individual SC
growth was assessed. The requirement for Matrigel for teratoma grow
of obvious cysts within the teratoma are summarized (n=3 or 6 mice/
intramuscular teratoma harvested after 12 weeks. Upper panel,
(ectodermal), and Mes (mesodermal) structures at high magnificatioWe observed areas of very intense proliferation, where
almost every present cell was positive, and others with very
low levels of proliferation (Fig. 2D).natomical locations. (A) Approximately 106 hESC in clumps were
ID mice. All mice were sacrificed after 8 weeks, and teratoma
th, the development of detectable teratomas, and the formation
group as indicated). (B) Typical histology of a well-differentiated
low magnification (5×). Lower panels, End (endodermal), Ect
n (40×).
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location and because we intended to quantify our studies, we
developed a generic and fast scoring method that allowed us
to screen large numbers of animals without using a caliper
(Fig. 3A): no teratoma is assigned grade 0; when a teratoma
becomes just detectable the animal is scored with “1”; when
the teratoma is clearly visible we score the animal with “2”;
and only when the teratoma is large and impedes locomotion
we grade it “3”, which coincides with the time of harvest.
Fig. 3B confirms the robustness of this method by comparing
it to caliper measurements; note that the diameters of hind
legs with grade 1 teratomas are on average significantly
different compared to controls (6.32 mm on a normal hind
leg of a naïve mouse compared to 10.55 mm at grade 1).
Other figures throughout this paper show data derived by this
simple scoring method.
Teratoma formation by differentiated
cell populations
To attempt to quantify differences in tumor-forming capacity
in hESC populations, we next applied our intramuscular
scoring to characterize differentiated hESC populations.
Fig. 4A shows the growth kinetics of undifferentiated hESC in
comparison to hESC that were differentiated according to a
12-day cardiomyocyte protocol (Graichen et al., 2007) or a
lengthy 42-day protocol that induces beta-like cells from
hESC (Phillips et al., 2007). We found that the growth
kinetics of teratoma formation among the three differentFigure 3 Development of a simple grading system for visible intra
injected into the hind leg of individual SCID mice. A simple gradin
teratoma; 1=teratoma just visible; 2=teratoma clearly visible; and 3
harvested when grade 3 is achieved. The right panel shows the gross m
The maximum upper hind leg diameters were measured using a ma
correlate well with the grade assigned by simple visual inspection.
different from the hind leg diameter of naïve animals (one-way ANOcell populations were similar, showing that high numbers of
pluripotent cells were still present in all three cell prepara-
tions. This result clearly illustrates the safety concerns
associated with purportedly “differentiated” hESC-derived
material intended for human transplantation.
Histological characterization of teratoma specimens by a
certified pathologist revealed that the germ-layer distribu-
tion was slightly altered when differentiated cells were used.
Teratomas derived from undifferentiated hESC cultures have
a significant bias toward mesoderm (67%), with little
endodermal (20%) and even less ectodermal (13%) compo-
nents (Fig. 4B). We found throughout our studies that this
germ-layer distribution for hES3 was similar when numerous
alternative hESC lines were tested as undifferentiated cell
populations in the same immodel. We present an overview of
representative data of germ-layer distributions of six cGMP-
compliant hESC lines in Suppl. Fig. 1A, in which average
percentages (68% mesoderm, 19% endoderm, and 13%
ectoderm) approach the hES3 data (Fig. 4B). Notably,
cardiomyocyte-like cell populations derived from hESC
gave rise to teratomas with more than double the endoder-
mal component at the expense of mesoderm/ectoderm (Fig.
4B, Suppl. Fig. 2A), which is in line with the upregulation of
endodermal markers such as Sox17 observed in the latter
differentiation protocol (Graichen et al., 2007). This shift
was less pronounced when beta cell-like hESC cultures were
used. It is noteworthy that in contrast to the germ-layer
distribution observed in the teratomas shown in Figs. 1, 2,
and 6 and in Suppl. Fig. 2B, most spontaneous maturemuscular teratomas. (A) Approximately 106 hESC in clumps were
g scale for monitoring teratoma development is shown: 0=no
= large teratoma, locomotion impeded. Teratomas are routinely
orphology of a grade 3 teratoma, with a typical weight≥1 g. (B)
nual caliper (n=10 mice/group). The average diameters (±SD)
Note that even the hind leg diameter for grade 1 is significantly
VA/Bonferroni; ⁎⁎ indicates a P valueb0.01).
Figure 4 Teratoma formation initiated with either undifferentiated or differentiated hESC populations. (A) Undifferentiated hESC
(left), hESC subjected to cardiomyocyte differentiation (middle), or hESC differentiated according to a multistep protocol favoring
definitive endoderm/beta cell generation (right) were injected as cell clumps intramuscularly (approximately 106 cells/mouse).
Teratoma formation was visually assessed according to the method described in Fig. 3. All injected cell populations formed detectable
tumors within 8 weeks. (B) Histopathological distribution of primary germ-layer derivatives in teratomas of assorted hESC origins (for
teratoma histology pictures, see Suppl. Fig. 2A). The first three cell preparations were injected im, except that beta cells were
injected im and into the kidney capsule. The n numbers given refer to germ-layer assessments for independent experiments. Average
percentage of tissue prevalence±SD is shown.
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biased toward ectoderm (N50%, Suppl. Fig. 1B), and they are
mostly benign teratomas categorized as type I (Blum and
Benvenisty, 2008). These spontaneous human teratomas are
often cystic, and presumably derived from ectodermal
differentiation of pluripotent cells close to ES cells.
Titration of colonies of undifferentiated hESC in the
im SCID model
We next aimed to increase the sensitivity of the im SCID
model, with the ultimate goal of possibly quantifying the
minimal number of undifferentiated hESC capable of seeding
a teratoma. hESC in clumps or colonies were mixed with
known numbers of nontumorigenic CCD919 human foreskin
fibroblasts that serve as an inert substrate. We also reasoned
that using a fibroblast line used in hESC culture may increase
the sensitivity of the teratoma model, compared to other
non-neoplastic cells similar to the study of Lawrenz et al.
(2004). hESC clumps expectedly gave rise to teratomas in 3/3
mice within 6 weeks, whereas only 2/3 mice inoculated im
with 10 hESC colonies (approximately 30 000 hESC/colony)
developed teratomas within 11 weeks (Fig. 5A). Spiking 10
hESC colonies into CCD919 fibroblasts accelerated teratoma
formation significantly, and increased the take rate (3/3
teratomas in 8 weeks). CCD919 never formed a tumor mass
(Fig. 5A), even beyond 20 weeks (not shown). We next
addressed whether increasing numbers of hESC coloniesspiked into CCD919 fibroblasts would decrease the time
required for teratoma formation. We mixed 2, 5, 10, and 20
colonies with 106 CCD919 fibroblasts (Fig. 5B). Indeed, 20
colonies/animal rapidly formed teratomas in 3/3 animals
that were detectable after only 5 weeks, reached grade 3 at
week 8, and at this point were fully mature displaying a
haphazard arrangement of tissues representative of all 3
germ layers (Suppl. Fig. 2B). Consistently, 5 and 10 colonies
formed teratomas more slowly, and 2 colonies were slowest,
requiring a full 12 weeks to yield a detectable tumor in 3/3
animals. When the colony number was plotted against the
time required to detect teratomas, a strong linear correla-
tion was observed (r2=0.95, Fig. 5C). In summary, it is
possible to approximately correlate hESC numbers with the
time required for teratoma growth in a sensitive system such
as the described CCD919 spiking/SCID mouse model.
Titration of single-cell suspension in the im
SCID model
Finally, we performed a number of experiments where we
mixed single-cell hESC dispersed by trypsin digestion with
106 CCD919 fibroblasts in order to define the minimal hESC
number required to seed teratoma formation (Fig. 6). In the
experiment shown in Fig. 5A, the largest hESC bolus (2×106
cells) gave rise to a detectable tumor within only 3 weeks
and reached grade 3 at week 5 (Fig. 6A), whereas the lowest
number of hESC (245 cells) required 12 weeks until grade 3 of
Figure 5 Teratoma formation on injection of limiting numbers
of hESC colonies. (A) Approximately 106 hESC in clumps, intact
hESC colonies alone or in combination with 106 mitomycin C-
treated CCD919 feeder cells, or feeder cells alone were injected
into the hind leg of SCIDmice as indicated. Teratoma formationwas
visually assessed according to the method described in Fig. 3 (3
mice/group for all conditions). (B) Decreasing numbers of hESC
colonies were mixed with 106 mitomycin C-treated CCD919 cells
and injected intramuscularly (3 SCID mice/group). (C) Correla-
tion of hESC colony number (log 10) with the time required to
achieve grade 1 (in weeks). For histology, see Suppl. Fig. 2B.
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correlative relationship between cell number and time
required to reach grade 1 as shown in Fig. 6B. Notably, the
harvested teratoma at week 5 generated from 2×106 hESC
displayed a stromal immature tumor histology (Fig. 6C),
classifying this lesion as an immature teratoma. Tumors with
a similar histological appearance in human patients are
considered malignant (teratocarcinomas) and are routinely
treated based on their grade and stage. In contrast, a
teratoma harvested at week 8 derived from a bolus of 1950
hESC showed a fully mature phenotype with all three germ
layers present (Fig. 6C).Repeating this study format with various cultures of hES3
(as used throughout Figs. 1–5), we noted that varying success
of teratoma formation did not correlate with an abnormal
karyotype or with passage number, but rather with the cell
subline adaptation to trypsin digest. We more systematically
addressed this difference with an independent hESC line in
Figs. 6D and E. Collagenase-passaged ESI-017 hESC did not
generate teratomas when single-cell digested with trypsin
and spiked into CCD919 cells as described above, whereas
trypsin-adapted (N5 passages) ESI-017 hESC (Ellerstrom et
al., 2007; Hasegawa et al., 2006; Phillips et al., 2008a,
2008b) readily gave rise to teratomas, at least when higher
cell numbers N1000 cells were used. Importantly, the single-
cell-adapted ESI-017 line used in our experiments was
karyotyped and used at passages below 30. This line
maintained a normal, diploid karyotype at least up to
passage 39 (cf. Fig. 2B in Phillips et al., 2008b). We conclude
that it is possible to generate teratomas from low numbers of
single-cell hESC, but the success of this approach depends on
the specific hESC line and its trypsin adaptation.Discussion
A number of recent publications addressed various aspects of
teratoma formation from hESC such as terminology, clonality
of tumors, and transplantation sites (Blum and Benvenisty,
2007, 2008; Damjanov and Andrews, 2007; Lensch and Ince,
2007; Prokhorova et al., 2008), but none of these confronted
experimentally the important quantification and safety
concerns regarding future cell therapy products derived
from hESC (reviewed in Halme and Kessler, 2006; Hentze et
al., 2007). In our study, we sought to establish several critical
parameters for future hESC safety studies such as the
robustness of teratoma formation, quantification, time
scale, and the minimal cell numbers required to form a
teratoma. We found that hESC cell injection into the hind leg
of SCID mice reproducibly generated fully differentiated
teratomas that can be easily graded and followed over time,
even when using 1/4000 (or 0.025%) of undifferentiated hESC
spiked into nontumorigenic feeder fibroblast cells that
support hESC growth in vitro. Figs. 5 and 6 suggest that the
high reproducibility and sensitivity of our SCID model are
directly attributed to mixing hESC with feeder cells. Further
studies using single-cell-adapted hESC cultures will deter-
mine whether the absolute detection limit can be increased
further, a goal which is predicated on the development of
experimental methods that produce viable single-cell sus-
pensions of hESC (Ellerstrom et al., 2007; Hasegawa et al.,
2006; Phillips et al., 2008a, 2008b).
During a meeting in April 2008 organized by the US FDA,
Geron, a biotech company based in Menlo Park, California,
showed that undifferentiated hESC when mixed with non-
tumorigenic, hESC-derived oligodendroglial progenitor cells
and injected into the spinal cord of immunodeficient mice
developed teratomas within 12 months only when 10% or
more of hESC were present (FDA, 2008b). For comparison,
the FDA/CBER 2006 guideline recommends testing 108
vector-producing cells for the presence of any replication-
competent retrovirus, assuming the assay would be sensitive
enough to pick up a single infected cell, a number many
magnitudes greater than the current techniques available for
Figure 6 Teratomas formed by limiting dilutions of hESC spiked into human feeder cells. (A) Serial dilutions of trypsinized single-cell
hESC were mixed with 106 mitomycin C-treated CCD919 human feeder cells before injection intramuscularly into SCID mice. Feeder
only injections served as negative controls. Mice were visually monitored for as many as 12 weeks, and were euthanized whenever a
grade 3 teratoma was observed. (B) Values in A were converted and replotted as a correlation between log hESC number (x-axis) and
time in weeks until a grade 1 teratoma was detected. (C) Comparison between teratomas generated from 2×106 and 1950 hESCs.
Detailed histological analysis of the 1950 hESC-derived teratoma reveals hypernucelated neuroectodermal structures; glandular
endoderm; cartilage surrounded by ossified structures (mesodermal origin). (D) The hESC line ESI-017 (grown on human feeders) was
passaged by Collagenase digest formore than 5 passages, trypsinized into single cells, spiked into CCD919 fibroblasts, and then injected
as shown in A; no teratomas emerged. (E) Similarly, ESI-017 (grown on human feeders) was passaged by trypsin digest for more than 5
passages, trypsinized into single cells, spiked into CCD919 fibroblasts, and injected as shown in A. Here, teratomas emergedwhen 104 or
105 cells per animal, but not when 103 cells, were used. Without spiking into CCD919 fibroblasts, no teratomas were detected as well.
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206 H. Hentze et al.quantifying residual hESC numbers (FDA, 2006). The hESC
detection limit established in our current study would be
sufficient to detect the difference between hESC contam-
ination of 1/1000 and 1/10 000; one would theoretically
require 100 mice to test a 108 hESC bolus. The question
nevertheless remains which safety margins will eventually be
set by the FDA for all future hESC applications (FDA, 2008a;
Hentze et al., 2007).
One critical variable for hESC safety studies is the immune
status of the host mouse strain, as it is evident that the
teratoma assay becomes increasingly more sensitive the
greater the immune deficiency. A study by Drukker et al.
established that T cells play a crucial role in the xenorejec-
tion of implanted hESCs by comparing undifferentiated hESCs
in immunocompetent versus immunodeficient mice (Drukker
et al., 2006). Immunocompetent mice did not develop
teratomas within a month, whereas immunodeficient mice
differed in their ability to reject hESCs (e.g., NOD/SCID mice
developed tumors). Another study compared the suscept-
ibility of NOD/SCID (no B, Tcells) versus SCID/Beige mice (no
B, T, NK cells) toward teratoma formation after intramus-
cular implantation of hESCs. Tumors grew significantly faster
in the SCID/Beige mice, suggesting that NK cells play a major
role in xenorejection of implanted hESCs (Tian et al., 2006).
This result was confirmed in a recent study performed with
mESC in a xenogenic rat model (Dressel et al., 2008). In
agreement with the notion above, we observed that in our
SCID mice experiments, suboptimal cell viability indeed can
lead to failure of hESC cell engraftment. It may therefore be
possible to greatly increase the sensitivity of this teratoma
model by several magnitudes with fully immunocompromised
mice (e.g., NOD/SCID/IL2Rγnull) and much longer observa-
tion periods. In addition, it is noteworthy in this context that
in the cancer stem cell field, at least two recent studies
managed to increase the detection limit of rare cancer stem
cells in a primary tumor—typically cited at around 1/106. By
using NOD/SCID/IL2Rγnull or nonirradiated congenic mice,
extending the observation period to many months and
applying Matrigel, the frequency of tumor-initiating cancer
stem cells was found to be in the area of 4–10% rather than
0.001% (Kelly et al., 2007; Quintana et al., 2008). Another
important consideration is a potential drawback due to
differences in tumor growth kinetics and immune status
when using immunodeficient mice as a xenogenic system for
safety studies. As discussed in detail elsewhere (Hentze et
al., 2007), the sensitivity of such safety studies may be
greatly enhanced by using better immunodeficient mouse
strains or by spiking hESC into suitable cellular substrates
(Fig. 6). These assays may still be magnitudes less sensitive
compared to the transplantation into a patient for three
reasons: (i) most importantly, the time scales of such in vivo
experiments greatly differ, and even if we were to extend
the safety models to 6 or even 12 months, we expect a future
cell therapy product to persist in the patient for years which
poses a problem as little is known about the potential safety
issues with low numbers of long-time surviving undifferen-
tiated hESC; (ii) the effects of interspecies transplantation
on the efficacy of engraftment and tumorigenicity are
largely unknown; and (iii) the effective difference between
immunosuppression versus immunodeficiency on the out-
come on such experiments may be another crucial factor to
be considered. A recent study by Shibata et al. illustrates allthe above factors (Shibata et al., 2006). Unselected
hematopoietic precursors differentiated from Cynomolgus
monkey embryonic stem cells did not form tumors when
transplanted into immunodeficient SCID mice (xenogenic,
immunodeficient) or in fetal sheep liver (xenogenic, immu-
noprivileged), but they did form lethal tumors within 2–3
months when transplanted back into Cynomolgus monkeys
(autologous, no immune suppression/deficiency), demon-
strating that autologous hESC transplantation is much more
conducive to tumor formation when compared to any other
setting.
It is generally believed that extended in vitro differentia-
tion results in decreased teratoma formation, as exemplified
in an earlier study using hESC differentiated into neuronal
cells and transplanted into rat brains (Brederlau et al.,
2006). Remarkably, a recent paper by Kroon et al. showed
that hESC-derived preparations of predominantly definitive
endoderm/pancreatic progenitors rarely formed teratomas
(1/46 or 2.2%) when transplanted into the epididymal fat pad
(Kroon et al., 2008). In contrast, our own studies (cf. Fig. 4A)
and comparable studies using endodermal and cardiomyo-
cyte differentiation protocols of ESC (Cai et al., 2007;
Fujikawa et al., 2005; Graichen et al., 2007; Phillips et al.,
2007) showed that ESC differentiated even over extended
periods of time are still able to form teratomas. Again, at
present there is no formal FDA guideline on how the
contamination of a given clinic-ready cell population by
hESC should be measured in a “gold standard” tumor assay.
Can teratoma formation be prevented experimentally
prior to transplantation of clinical material of hESC origin?
One potential method is to eliminate rogue undifferentiated
cells by selectively removing them based on their well-
defined cell-surface marker profile (e.g., SSEA-4+, Tra1-60+,
and Tra1-81+) using a combination of antibodies and sorting
by FACS or MACS (reviewed in FDA, 2008a; Hentze et al.,
2007). An alternative antibody-based approach was recently
described that employed a cytotoxic monoclonal antibody
(mAb 84) that recognizes the cell-surface molecule Podoca-
lyxin-like Protein-1 that is specifically expressed on undif-
ferentiated, but not differentiated, hESC (Choo et al.,
2008). In our own laboratory using the described im SCID
mouse model, we found that teratoma formation was
eliminated in SCID mice when hESC or NCCIT embryonal
carcinoma cells were pretreated with mAb 84 prior to hind
limb injection. Despite the promise of these techniques,
several challenges exist, including the development and
expense of cGMP-compliant antibodies, the preparation of
differentiated hESC that are viable as single cells and,
importantly, remain efficacious after transplantation, and
the length of time of the selection technique itself. A
genetic-based selection technique that is very effective at
eliminating teratoma formation in the im SCID mouse
model has also been described (Xu et al., 2008): Xu et al.
from ES Cell International engineered hES-3 to express the
neomycin-resistance gene under the control of the cardio-
myocyte-specific α-myosin heavy chain (α-MHC) promoter.
Differentiation and G418 selection produced nearly 100%
pure cultures of cardiomyocytes. Notably, intramuscular
transplantation of approximately 1×106 of these cells
yielded no teratomas. This encouraging result suggests that
highly purified progenitors or terminally differentiated cell
types derived from hESC will mitigate the safety concerns
207Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studiessurrounding heterogeneous cell preparations and the tumor-
promoting cells they conceal.
There are numerous disagreements among the teratoma
studies in the current literature, which can be attributed to
different experimental settings, minute procedural details,
or interpretation of results. In our experience, even minor
variations in cell harvest procedures (centrifugation, pipet-
ting), in timing from cell harvest to inoculation (b1 h), and
most importantly in the injection procedure itself (which
requires two trained operators, one to restrain the animal
and one to inject the cells) can hamper reproducibility. For
this reason, we rigorously used SOPs and detailed record
sheets for these experiments. For instance, a recent report
by Prokohora et al. found that the muscle is inferior to the
subcutaneous space for hESC injection as only 1 of 8 mice
developed a teratoma (Prokhorova et al., 2008). However,
the methods for injection, the hESC lines, and hESC culture
methods as well as the mouse strains used all differed from
our study. Furthermore, the animal numbers in the above
study as well as in our pilot study comparing different
anatomical locations (Fig. 1) are quite limited due to the
resource-intensive nature of such comparative in vivo
studies. Lastly, submicroscopic changes such as SNP profile
changes that, for instance, influence the replating efficiency
of hESC lines (Hasegawa et al., 2006) may also contribute to
differences in teratoma formation, an issue that would
warrant additional comparative teratoma studies. As
another example, the insulin-producing hESC-derived grafts
recovered after 56 days in a study by Eshpeter et al. display
bona fide teratoma histology (Eshpeter et al. 2008; Kroon et
al., 2008), similar to outgrowths described in our own
previous work (Phillips et al., 2007). Although the authors
provide evidence of moderate clinical efficacy, the impor-
tant question of tumorigenicity and safety cannot be over-
looked. In conclusion, a gold standard for testing hESC-
derived cell therapy products in an in vivo model is highly
desirable for comparing the potential safety issues arising
from these heterogeneous preparations.Materials and methods
hESC culture
For most experiments, hES3 (Reubinoff et al., 2000) or its
derivate GFP-hES3 (Costa et al., 2005) were used; addi-
tional hESC lines hES2, hES4, ESI-014, ESI-017, ESI-035, ESI-
049, ESI-051, and ESI-053 were employed where indicated.
hESC were grown on γ-irradiated human foreskin fibroblasts
(CCD919, ATCC) (Crook et al., 2007), routinely plated at a
density of 3×105 cells/cm2. Prior to use, feeder plates were
conditioned overnight in hESC medium containing KO-
DMEM, 1% nonessential amino acids, 1×penicillin/strepto-
mycin, 2 mM L-glutamine, and 20% KOSR (all reagents from
Invitrogen) and supplemented with 50 μg/ml bFGF (Strath-
man). hESC passaging or harvesting was performed using
Collagenase NB6 (Serva, 1.25 mg/ml for 4 min). Treated
plates were rinsed with PBS and replenished with hESC
medium. The entire surface area of the plate was then
streaked with a 2 ml disposable plastic pipette
at approximately 2-mm intervals. The cells were harvested
with a cell scraper and transferred to new feeder plates.The cells were split every 7 days at an approximate split
ratio of 1:3 to 1:5.
Single-cell hESC adaptation was performed according to
protocols described previously (Ellerstrom et al., 2007;
Hasegawa et al., 2006; Phillips et al., 2008a, 2008b). Briefly,
hESC were dissociated using TrypLE (Invitrogen) for 5 min,
gently triturated, diluted with 3 ml medium, passed through
a cell strainer (70 μm), and plated at a density of 5.5×104
hESC/cm2 on an Ortec feeder layer. The cells were split every
7 days with approximately 1/7 split ratios.
Preparation of hESC suspensions for transplantation
For routine inoculation of 3 mice, a 10-cm plate of
undifferentiated hESC (typically yielding 3– 5×106 hESC) or
an equal amount of differentiated hESC generated as
described previously (Graichen et al., 2007; Phillips et al.,
2007) was washed once with PBS and harvested with a cell
scraper. The cell suspension was collected into a 15-ml falcon
tube and spun down at 2000 rpm for 4 min. The cell pellet was
carefully resuspended by stepwise addition of either room
temperature PBS or a 1:1 mixture of PBS:Matrigel (BD
Biosciences) to a final total volume of 150 μl (kept on ice), or
mixed with 106 mitomycin C-treated CCD919 fibroblasts
(viability N95%) that were previously shown to support hESC
growth in vitro. Just prior to inoculation (b1 h after cell
harvest), the cell suspension was equally divided into three
tubes. Alternatively, individual hESC colonies (typically 30 000
hESC/colony as assessed by trypsin digest of individual
colonies) were manually dislodged by cutting with a glass
capillary tube, or single-cell suspensions of defined hESC
numbers were generated. These samples were resuspended
and prepared for injection as described above.
For beta cells or cardiomyocytes derived from long-term
protocols using hES3 or GFP-hES3 cells (Phillips et al., 2007;
Graichen et al., 2007), cell aggregates were physically
disrupted by forcing a dilute cell suspension (content of a
10-cm plate in 5 ml) through a series of needles with
progressively decreasing diameter (G21, G23, G25, G27).
Digestions of parallel cell samples were performed using
TrypLE (Invitrogen) for 5 min to estimate cell numbers.
hESC inoculation into various transplantation sites
in mice
All studies were undertaken with prior approval from BRC
(Biological Resource Center, Biopolis Singapore) Institutional
Animal Care and Use Committee (IACUC No. 050008), and the
National University of Singapore Institutional Review Board
(NUS IRB No. 05-020). Male SCID mice (8–12 weeks age) were
used for all experiments. All procedures were carried out in a
biological safety cabinet under sterile conditions using
sterile materials.
hESC suspensions (50 μl) were injected intramuscularly,
subcutaneously, or intraperitoneally without anesthesia. For
im injections, a sterile 1 ml syringe with a 23G needle was
guided into the hind leg quadricep along its long axis and
toward the muscle center. Injections of hESC into the kidney
capsule, testis, epididymal fat pad, and liver were done
under anesthesia. Mice received the following anesthetics
and analgesics: Hypnorm (fentanyl/fluanisone, 0.2 ml/kg) or
208 H. Hentze et al.ketamine (75 mg/kg ip)/Medetomidine (0.1 mg/kg ip), and a
single dose of the antibiotic cephalexin 15 mg/kg (sc). Kidney
capsule injections were carried out essentially as described
(Nagy et al., 2003) with the following modifications: a 50-μl
Hamilton syringe was attached to transparent, flexible HPLC
grade tubing (inner diameter: 0.3 mm, length: 1.5 cm) that
was used to deliver hESC suspensions into the renal
subcapsular space. The tubing probed no further than 2 to
3 mm beyond the small opening in the kidney capsule before
the cell material was discharged with gentle and constant
pressure. The body wall was sutured with 3 stitches using
absorbable suturing material, and the dermis with another
3–5 stitches using nonabsorbable suturing material.
For hESC injection into the testis, a 1-cm longitudinal
incision in the abdominal wall was made, and the testis
exteriorized. hESC were inoculated into the testis parench-
yma with a modified Hamilton pipette, and the wound was
sutured as described above. For hESC injection into the
epididymal fat pad, a 1- to 2-cm ventral midline incision
(first the epidermis, then the body wall) was made. The
testis with the attached epididymal fat pad was exposed,
and the hESC suspension injected into the center of the fat
pad using a 23G needle, followed by suturing of the wound.
For injection of hESC into the liver, a short dorsal midline
incision was made just below the sternum (2–3 cm),
(epidermis, then body wall). The large left liver lobe was
exposed, and the hESC suspension slowly injected into the
center of the large lobe using a 27G needle. Correct
injection was visibly monitored by a rapid color change in
the liver lobe (from red to light brown to red). After
successful injection, the needle was retracted swiftly, the
injection site was pressed with a cotton swab for about
1 min, and then a sterile, resorbable wound pad was placed
at the injection site.
Quantification of teratoma formation
Teratomas developing in the testis, kidney capsule, liver, or
epididymal fat pad are not readily visible, whereas those
growing sc can be easily seen and measured using the
traditional caliper method. For im inoculations, which were
used most extensively in this study, teratoma formation was
monitored visually using a simple grading system that was
confirmed by caliper measurements: grade 0=no teratoma
visible (6.32-mm average maximal hind leg diameter, n=10
for all groups); grade 1=teratoma just detectable (10.55 mm
average); grade 2=teratoma obvious (13.2 mm average); and
grade 3=teratoma impedes locomotion (14.52 mm average).
Grade 3 teratomas typically weigh 1–2 g and are harvested
and processed for histology.
Tissue preparation, immunohistochemistry,
and assessment of germ-layer distribution
After euthanasia of mice with rising CO2 levels, teratomas
were carefully excised from the surrounding muscle tissue,
cut into 0.5-g pieces and fixed in Bouin's solution followed by
paraffin sectioning. Five-micrometer sections were cut
(Leica RM2255), and stored at 4 °C prior to staining or
immunohistochemistry. All hematoxylin and eosin and
immunostains were performed according to standard proto-
cols. Teratomas were assessed by a board-certified pathol-ogist at the Department of Pathology, National University of
Singapore (T. Putti). As routinely performed in histology
assessments of naturally occurring human teratomas, the
composition of each teratoma was estimated semiquantita-
tively by visual inspection of H&E-stained sections in a
blinded fashion. Differentiated elements in the teratomas
were classified into ectodermal (skin, neural, etc.), endo-
dermal (glandular structures), and mesodermal (cartilage,
bone) components as a percentage of entire tissue. The
remaining undifferentiated spindle stromal component was
included under mesoderm.
Immunostaining was performed using the DAB detection
system (Vectastain peroxidase, Vector Labs). Slides were
counterstained with hematoxylin to identify nuclei. Primary
antibodies used were anti-desmin (clone D39 from Dako, 1/
50); anti-GFAP (mouse monoclonal clone 6F2 from Serotec,
1/50); anti-endoA cytokeratin (Troma-1 from Developmental
Studies Hybridoma Bank, 1/20); and anti-Ki67 (MM1/Lki67
clone from Novocastra, 1/50).
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